Rezolute, Inc. (RZLT)
| Market Cap | 53.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.30M |
| Shares Out | 8.05M |
| EPS (ttm) | -3.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $6.55 |
| Previous Close | $6.41 |
| Change ($) | 0.14 |
| Change (%) | 2.18% |
| Day's Open | 6.45 |
| Day's Range | 6.40 - 6.93 |
| Day's Volume | 27,588 |
| 52-Week Range | 6.05 - 21.11 |
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcomi...
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.
RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of...
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name ... [Read more...]
| Industry Biotechnology | Founded 2010 |
| CEO Nevan Elam | Employees 23 |
| Stock Exchange NASDAQ | Ticker Symbol RZLT |
Analyst Forecasts
According to 2 analysts, the average rating for Rezolute stock is "Buy." The 12-month stock price forecast is 31.50, which is an increase of 380.92% from the latest price.